| |
|
Product Name:
|
MVs/Tennessee.USA/12.25, Genotype D8
|
|
Ownership statement:
|
This reagent is the property of the U.S. Government.
|
|
Manufacturer:
|
BEI Resources
|
|
Taxonomy:
|
Virus Classification: Paramyxoviridae, Morbillivirus
Species: Measles Virus
Strain/Isolate: MVs/Tennessee.USA/12.25
Genotype: D8
|
|
Additional Information:
|
MeV is a single-strand negative sense non-segmented RNA virus.2 MeVs are divided into 8 clades, designated A through H, with 24 genotypes based on the sequences of the hemagglutinin (HA) and nucleoprotein (N) genes. The sequence of the 450 nucleotides that encode the carboxyl-terminal 150 amino acids of the nucleoprotein (N-450) is needed to determine the genotype.2,3 In 2018, four new genotypes were identified: B3, D4, D8 and H1. In 2000, measles was declared eliminated in the US by the WHO, but in 2019 the highest numbers of cases and outbreaks were reported.4
|
|
Material Provided:
|
Each vial contains approximately 1 mL of cell lysate and supernatant from Chlorocebus aethiops kidney epithelial cells expressing human signaling lymphocytic activation molecule (Vero-hSLAM) cells infected with MeV, MVs/Tennessee.USA/12.25 (D8).
Note: If homogeneity is required for your intended use, please purify prior to initiating work.
|
|
Packing/Storage:
|
NR-60832 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.
|
|
Growth Conditions:
|
Host: Chlorocebus aethiops kidney epithelial cells expressing human signaling lymphocytic activation molecule (Vero-hSLAM; BEI Resources NR-55500)
Growth Medium: Eagle’s Minimum Essential Medium containing Earle’s Balanced Salt Solution, non-essential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, and 1.5 g/L of sodium bicarbonate supplemented with 2% fetal bovine serum, or equivalent
Infection: Cells should be 80% to 90% confluent
Incubation: 3 to 5 days at 37°C and 5% CO2
Cytopathic Effect: Syncytia formation
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products. |
References:
|
1. Prince-Guerra, J., Personal Communication.
2. Coughlin, M. M., et al. “Perspective on Global Measles Epidemiology and Control and the Role of Novel Vaccination Strategies.” Viruses 9 (2017). PubMed: 28106841.
3. Magana, L. C., et al. “Complete Genome Sequences of Mumps and Measles Virus Isolates from Three States in the United States.” Genome Announc. 33 (2017). PubMed: 28818890.
4. Patel, M., et al. “National Update on Measles Cases and Outbreaks – United States, January 1 – October 1, 2019.” MMWR 40 (2019): 893-896. PubMed: 31600181.
|
|
Citation:
|
Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Measles Virus, MVs/Tennessee.USA/12.25, Genotype D8, NR-60832."
|
|
Biosafety Level:
|
2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|